Cronos Group (TSE:CRON) Trading Down 4.1% – What’s Next?

Cronos Group Inc. (TSE:CRON)’s stock price dropped 4.1% during trading on Tuesday . The stock traded as low as C$3.76 and last traded at C$3.77. Approximately 203,340 shares were traded during trading, an increase of 15% from the average daily volume of 177,206 shares. The stock had previously closed at C$3.93.

Wall Street Analysts Forecast Growth

CRON has been the topic of several analyst reports. TD Securities set a C$4.50 price target on shares of Cronos Group and gave the company a “buy” rating in a report on Tuesday, February 24th. TD upped their price target on shares of Cronos Group from C$4.50 to C$5.50 and gave the company a “buy” rating in a report on Tuesday, May 12th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of C$4.75.

Cronos Group Price Performance

The company has a debt-to-equity ratio of 0.12, a quick ratio of 24.01 and a current ratio of 21.87. The firm has a market capitalization of C$1.41 billion, a P/E ratio of -188.00, a P/E/G ratio of 0.12 and a beta of 1.12. The stock’s 50 day simple moving average is C$3.63 and its 200 day simple moving average is C$3.63.

Cronos Group (TSE:CRON) last issued its earnings results on Monday, May 11th. The company reported C$0.06 EPS for the quarter. The business had revenue of C$62.86 million for the quarter. Cronos Group had a negative net margin of 1.29% and a negative return on equity of 0.19%. As a group, analysts expect that Cronos Group Inc. will post -0.26 earnings per share for the current fiscal year.

About Cronos Group

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.